Insights from 2024 ASCO® GU Annual Meeting


 

ASCO® GU 2024 Insights: "EMBARK Trial - Outcomes of Men With High-Risk Biochemically Recurrent Prostate Cancer Who Suspended Enzalutamide Monotherapy Treatment"

0 views
February 20, 2024
Comments 0
Login to view comments. Click here to Login